Triple
T10214729
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Avsola |
E242411
|
entity |
| Predicate | hasOriginatorReferenceProduct |
P92778
|
FINISHED |
| Object | Remicade |
E49851
|
NE FINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Remicade | Statement: [Avsola, hasOriginatorReferenceProduct, Remicade]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Remicade Context triple: [Avsola, hasOriginatorReferenceProduct, Remicade]
-
A.
Remicade
chosen
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Humira
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
E.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: hasOriginatorReferenceProduct Context triple: [Avsola, hasOriginatorReferenceProduct, Remicade]
-
A.
originatesAs
Indicates that one entity begins, arises, or comes into existence in the form, state, or role specified by another entity.
-
B.
hasReferenceID
Indicates that an entity is associated with a specific reference identifier used to uniquely track or distinguish it.
-
C.
originallyBelongedToOrder
Indicates that an entity was previously a member of or associated with a particular order, but is no longer.
-
D.
originallyBy
Indicates that one entity is the original creator, author, or source of another entity.
-
E.
hasOriginIn
Indicates that something begins, arises, or is derived from a specified source, place, or cause.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d381ae26c48190985abd0e25ee5d04 |
completed | April 6, 2026, 9:49 a.m. |
| NER | Named-entity recognition | batch_69d3aa273bdc8190bc4cf67a7923cebc |
completed | April 6, 2026, 12:42 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d90d54c32c8190b175a30c7c905cd2 |
completed | April 10, 2026, 2:46 p.m. |
| PD | Predicate disambiguation | batch_69d39559e5ac8190b88eca75956b7e6a |
completed | April 6, 2026, 11:13 a.m. |
| PDg | Predicate description generation | batch_69d3aa208c248190a0fb186b106389f3 |
completed | April 6, 2026, 12:42 p.m. |
Created at: April 6, 2026, 11:04 a.m.